Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence is PEG-modified, which is a functional group of the polypeptide and can increase the water solubility of the sequence. TirzepaChemicalbooktide main physiological function is glucose-dependent insulin nutritional polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.
*The following content is generated by AI and is for reference only.
Tirzepatide is a groundbreaking dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Its molecular formula is C164H253N49O47, with a CAS registry number of 2028363-73-6. This synthetic peptide functions as a first-in-class medication that mimics the action of two endogenous incretin hormones to regulate blood sugar levels and promote weight loss. By simultaneously activating both GIP and GLP-1 receptors, Tirzepatide offers a synergistic mechanism that enhances insulin secretion in a glucose-dependent manner while suppressing glucagon release, thereby reducing hepatic glucose production. Furthermore, it significantly slows gastric emptying and increases satiety signals in the brain, leading to substantial caloric reduction without causing hypoglycemia in non-diabetic individuals.
Clinically, Tirzepatide is primarily indicated for the treatment of type 2 diabetes mellitus under the brand name Mounjaro, where it effectively lowers HbA1c levels and improves glycemic control. More recently, it has gained widespread attention for its potent weight management capabilities when marketed as Zepbound for chronic weight management in adults with obesity or overweight conditions accompanied by comorbidities. Clinical trials have demonstrated superior efficacy compared to existing monotherapies, including semaglutide, resulting in significant percentage reductions in body weight. The drug is administered via once-weekly subcutaneous injection, offering convenience and adherence benefits over daily oral medications. While generally well-tolerated, common side effects include nausea, vomiting, diarrhea, and constipation, which are often transient. As a peptide-based biologic, it requires refrigeration prior to use. Tirzepatide represents a major advancement in metabolic medicine, providing a versatile therapeutic option that addresses both hyperglycemia and adiposity through a novel dual-hormone pathway, marking a new era in the management of metabolic disorders globally.
(All Rights Reserved)![6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one](https://eimg.pharmasources.com/image/20250617/4zoOybJjzUTk0UgguabMkX7VnrDIlxHluERwqkjK.jpg)
